GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005140219 | Esophagus | HGIN | neuron apoptotic process | 52/2587 | 246/18723 | 1.01e-03 | 1.26e-02 | 52 |
GO:004352520 | Esophagus | HGIN | positive regulation of neuron apoptotic process | 17/2587 | 58/18723 | 1.64e-03 | 1.82e-02 | 17 |
GO:007190016 | Esophagus | ESCC | regulation of protein serine/threonine kinase activity | 227/8552 | 359/18723 | 1.12e-11 | 4.10e-10 | 227 |
GO:0016049110 | Esophagus | ESCC | cell growth | 289/8552 | 482/18723 | 1.29e-10 | 3.77e-09 | 289 |
GO:000155819 | Esophagus | ESCC | regulation of cell growth | 248/8552 | 414/18723 | 2.97e-09 | 6.45e-08 | 248 |
GO:0070997111 | Esophagus | ESCC | neuron death | 216/8552 | 361/18723 | 3.49e-08 | 6.45e-07 | 216 |
GO:003253520 | Esophagus | ESCC | regulation of cellular component size | 227/8552 | 383/18723 | 4.77e-08 | 8.60e-07 | 227 |
GO:003109818 | Esophagus | ESCC | stress-activated protein kinase signaling cascade | 154/8552 | 247/18723 | 8.53e-08 | 1.44e-06 | 154 |
GO:00510908 | Esophagus | ESCC | regulation of DNA-binding transcription factor activity | 252/8552 | 440/18723 | 5.22e-07 | 6.97e-06 | 252 |
GO:005140318 | Esophagus | ESCC | stress-activated MAPK cascade | 147/8552 | 239/18723 | 5.43e-07 | 7.18e-06 | 147 |
GO:004484314 | Esophagus | ESCC | cell cycle G1/S phase transition | 148/8552 | 241/18723 | 5.68e-07 | 7.48e-06 | 148 |
GO:00719029 | Esophagus | ESCC | positive regulation of protein serine/threonine kinase activity | 124/8552 | 200/18723 | 2.27e-06 | 2.61e-05 | 124 |
GO:004677710 | Esophagus | ESCC | protein autophosphorylation | 138/8552 | 227/18723 | 2.98e-06 | 3.38e-05 | 138 |
GO:00182099 | Esophagus | ESCC | peptidyl-serine modification | 196/8552 | 338/18723 | 3.07e-06 | 3.47e-05 | 196 |
GO:0051402110 | Esophagus | ESCC | neuron apoptotic process | 148/8552 | 246/18723 | 3.08e-06 | 3.47e-05 | 148 |
GO:001810515 | Esophagus | ESCC | peptidyl-serine phosphorylation | 184/8552 | 315/18723 | 3.22e-06 | 3.61e-05 | 184 |
GO:1901214111 | Esophagus | ESCC | regulation of neuron death | 186/8552 | 319/18723 | 3.35e-06 | 3.73e-05 | 186 |
GO:00510918 | Esophagus | ESCC | positive regulation of DNA-binding transcription factor activity | 155/8552 | 260/18723 | 3.83e-06 | 4.14e-05 | 155 |
GO:002260420 | Esophagus | ESCC | regulation of cell morphogenesis | 180/8552 | 309/18723 | 5.19e-06 | 5.45e-05 | 180 |
GO:004586018 | Esophagus | ESCC | positive regulation of protein kinase activity | 219/8552 | 386/18723 | 6.91e-06 | 6.97e-05 | 219 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0453026 | Endometrium | AEH | Tight junction | 54/1197 | 169/8465 | 1.99e-09 | 3.80e-08 | 2.78e-08 | 54 |
hsa0412016 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
hsa0472216 | Endometrium | AEH | Neurotrophin signaling pathway | 31/1197 | 119/8465 | 4.07e-04 | 3.07e-03 | 2.25e-03 | 31 |
hsa0516626 | Endometrium | AEH | Human T-cell leukemia virus 1 infection | 50/1197 | 222/8465 | 4.30e-04 | 3.11e-03 | 2.27e-03 | 50 |
hsa04530112 | Endometrium | AEH | Tight junction | 54/1197 | 169/8465 | 1.99e-09 | 3.80e-08 | 2.78e-08 | 54 |
hsa0412017 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
hsa0472217 | Endometrium | AEH | Neurotrophin signaling pathway | 31/1197 | 119/8465 | 4.07e-04 | 3.07e-03 | 2.25e-03 | 31 |
hsa05166111 | Endometrium | AEH | Human T-cell leukemia virus 1 infection | 50/1197 | 222/8465 | 4.30e-04 | 3.11e-03 | 2.27e-03 | 50 |
hsa0453027 | Endometrium | EEC | Tight junction | 54/1237 | 169/8465 | 6.56e-09 | 1.27e-07 | 9.46e-08 | 54 |
hsa0412023 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
hsa0516627 | Endometrium | EEC | Human T-cell leukemia virus 1 infection | 52/1237 | 222/8465 | 2.73e-04 | 2.36e-03 | 1.76e-03 | 52 |
hsa0472222 | Endometrium | EEC | Neurotrophin signaling pathway | 30/1237 | 119/8465 | 1.54e-03 | 9.55e-03 | 7.12e-03 | 30 |
hsa0453036 | Endometrium | EEC | Tight junction | 54/1237 | 169/8465 | 6.56e-09 | 1.27e-07 | 9.46e-08 | 54 |
hsa0412033 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
hsa0516636 | Endometrium | EEC | Human T-cell leukemia virus 1 infection | 52/1237 | 222/8465 | 2.73e-04 | 2.36e-03 | 1.76e-03 | 52 |
hsa0472232 | Endometrium | EEC | Neurotrophin signaling pathway | 30/1237 | 119/8465 | 1.54e-03 | 9.55e-03 | 7.12e-03 | 30 |
hsa0412018 | Prostate | BPH | Ubiquitin mediated proteolysis | 61/1718 | 142/8465 | 5.50e-10 | 9.07e-09 | 5.61e-09 | 61 |
hsa0453028 | Prostate | BPH | Tight junction | 68/1718 | 169/8465 | 1.70e-09 | 2.55e-08 | 1.58e-08 | 68 |
hsa0516628 | Prostate | BPH | Human T-cell leukemia virus 1 infection | 79/1718 | 222/8465 | 6.00e-08 | 6.83e-07 | 4.23e-07 | 79 |
hsa0401010 | Prostate | BPH | MAPK signaling pathway | 87/1718 | 302/8465 | 2.05e-04 | 1.13e-03 | 6.98e-04 | 87 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAP3K1 | SNV | Missense_Mutation | | c.4121A>G | p.Asn1374Ser | p.N1374S | Q13233 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A2-A04N-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
MAP3K1 | SNV | Missense_Mutation | | c.4310G>T | p.Cys1437Phe | p.C1437F | Q13233 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A04N-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
MAP3K1 | SNV | Missense_Mutation | | c.3989N>G | p.Ser1330Trp | p.S1330W | Q13233 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A0EU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAP3K1 | SNV | Missense_Mutation | | c.3517N>G | p.His1173Asp | p.H1173D | Q13233 | protein_coding | tolerated_low_confidence(0.12) | benign(0.395) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
MAP3K1 | SNV | Missense_Mutation | | c.2305C>T | p.Pro769Ser | p.P769S | Q13233 | protein_coding | tolerated(0.06) | benign(0.158) | TCGA-A2-A1G1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAP3K1 | SNV | Missense_Mutation | | c.4298N>C | p.Trp1433Ser | p.W1433S | Q13233 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A259-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
MAP3K1 | SNV | Missense_Mutation | | c.3934N>T | p.Ala1312Ser | p.A1312S | Q13233 | protein_coding | tolerated(0.06) | possibly_damaging(0.533) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
MAP3K1 | SNV | Missense_Mutation | novel | c.975N>A | p.Asn325Lys | p.N325K | Q13233 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
MAP3K1 | SNV | Missense_Mutation | novel | c.3373N>G | p.Asn1125Asp | p.N1125D | Q13233 | protein_coding | deleterious_low_confidence(0.01) | benign(0.03) | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | | SD |
MAP3K1 | SNV | Missense_Mutation | rs755757854 | c.1403N>C | p.His468Pro | p.H468P | Q13233 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | cisplatin | CISPLATIN | 21636554 |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | gefitinib | GEFITINIB | 21636554 |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | paclitaxel | PACLITAXEL | 21636554 |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 223366167 | E-6201 | |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | docetaxel | DOCETAXEL | 21636554 |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | erlotinib | ERLOTINIB | 21636554 |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | CHEMBL1097999 | E-6201 | |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | carboplatin | CARBOPLATIN | 21636554 |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | CI-1040 | CI-1040 | |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | Tumor necrosis factor alpha (TNF-alpha) inhibitors | | 27670765 |